Nexo Therapeutics Launches With $60 Million Series A Financing
07/26/23, 12:02 PM
Location
littletonMoney raised
$60 million
Industry
biotechnology
Round Type
series a
Investors
University Of Texas Md Anderson Cancer Center, Cormorant Asset Management, New Enterprise Associates, Versant Ventures
Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management. The company also announced a multi-year strategic research collaboration with The University of Texas MD Anderson Cancer Center, the details of which are described in a separate announcement.
Company Info
Location
11757 w. ken caryl avenue
littleton, colorado, united states
Additional Info
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD.